Your browser doesn't support javascript.
loading
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
Saad, Everardo D; Squifflet, Pierre; Burzykowski, Tomasz; Quinaux, Emmanuel; Delaloge, Suzette; Mavroudis, Dimitris; Perez, Edith; Piccart-Gebhart, Martine; Schneider, Bryan P; Slamon, Dennis; Wolmark, Norman; Buyse, Marc.
Afiliação
  • Saad ED; International Drug Development Institute, Louvain-la-Neuve, Belgium. Electronic address: everardo.saad@iddi.com.
  • Squifflet P; International Drug Development Institute, Louvain-la-Neuve, Belgium.
  • Burzykowski T; International Drug Development Institute, Louvain-la-Neuve, Belgium; Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium.
  • Quinaux E; International Drug Development Institute, Louvain-la-Neuve, Belgium.
  • Delaloge S; Unicancer Breast Group, Paris, France.
  • Mavroudis D; University of Crete, Heraklion, Greece.
  • Perez E; Mayo Clinic, Jacksonville, FL, USA.
  • Piccart-Gebhart M; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Schneider BP; Indiana University, Indianapolis, IN, USA.
  • Slamon D; University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
  • Wolmark N; NRG Oncology/Pittsburgh, Pittsburgh, PA, USA.
  • Buyse M; Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium; International Drug Development Institute, San Francisco, CA, USA.
Lancet Oncol ; 20(3): 361-370, 2019 03.
Article em En | MEDLINE | ID: mdl-30709633
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Intervalo Livre de Doença / Ado-Trastuzumab Emtansina Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Intervalo Livre de Doença / Ado-Trastuzumab Emtansina Idioma: En Ano de publicação: 2019 Tipo de documento: Article